Download PDF
Horm Metab Res 2002; 34(11/12): 703-708
DOI: 10.1055/s-2002-38247
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Influence of Antihypertensive Treatment with Perindopril, Pindolol or Felodipin
on Plasma Leptin Concentration in Patients with Essential Hypertension

J.  Ficek1 , F.  Kokot1 , J.  Chudek1 , M.  Adamczak1 , R.  Ficek1 , A.  Wieçek1
  • 1Department of Nephrology, Endocrinology and Metabolic Diseases, Silesian University School of Medicine, Katowice, Poland
Further Information

Publication History

Received 25 September 2002

Accepted after revision 5 December 2002

Publication Date:
27 March 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Leptin - produced predominantly by adipocytes - is presumably also involved in pathogenesis of essential hypertension (EH). In the present study, we addressed the question whether and to what extent antihypertensive monotherapy does influence leptinemia in patients with mild or moderate EH. Forty-two EH patients were enrolled in this randomized, open-labeled study. In all subjects, plasma concentrations of leptin, insulin, glucose, cholesterol, triglycerides and creatinine were estimated twice - before and one month after initiation of monotherapy with perindopril, pindolol or felodipin, respectively. Plasma leptin concentration, in the afternoon and midnight, was significantly higher in patients with essential hypertension than in normotensive healthy subjects (p < 0.01). Therapy with perindopril or felodipin did not influence the daily profile of leptinemia or insulinemia, respectively. However, pindolol monotherapy showed a marked (p < 0.01) suppressive effect on the daily profile of leptinemia, but did not influence insulinemia. Conclusions: First, patients with essential hypertension are characterized by higher plasma leptin levels as compared with normotensive healthy subjects; second, suppressive effect of pindolol on leptinemia may be of pathophysiological relevance in the course of weight gain during β-blocker therapy.

Key words

Essential Hypertension - Leptin - Antihypertensive Treatment - Perindopril - Felodipin - Pindolol

References

  • 1 Elisaf M. The treatment of coronary heart disease: an update. Part 1: An overview of the risk factors for cardiovascular disease.  Curr Med Res Opin. 2001;  17 18-28
    CrossrefPubMedGoogle Scholar
  • 2 Rimm B, Stampfer M J, Giovannucci E, Ascherio A, Spiegelman D, Colditz G A, Willett W C. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.  Am J Epidemiol. 1995;  141 1117-1127
    PubMedGoogle Scholar
  • 3 Kannel W B, Brand M, Skinner J J, Dawber T R, Mc Namara P M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study.  Ann Intern Med. 1967;  67 48-59
    PubMedGoogle Scholar
  • 4 MacMahon S W, Blacket R B, Macdonald G J, Hall W. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study.  J Hypertens. 1984;  2 85-91
    PubMedGoogle Scholar
  • 5 Ahima R S, Flier J S. Adipose tissue as an endocrine organ.  Trends Endocrinol Metab. 2000;  11 327-332
    PubMedGoogle Scholar
  • 6 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
    CrossrefPubMedGoogle Scholar
  • 7 Friedman J M, Halaas J L. Leptin and the regulation of body weight in mammals.  Nature. 1998;  395 763-770
    CrossrefPubMedGoogle Scholar
  • 8 Hall J E, Shek E WM, Brands M W. Does leptin contribute to obesity hypertension?.  Curr Opin Endocrinol Diabetes. 1999;  6 225-229
    CrossrefPubMedGoogle Scholar
  • 9 Mark A L, Correia M LG, Rahmouni K, Haynes W G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications.  J Hypertens. 2002;  20 1245-1250
    CrossrefPubMedGoogle Scholar
  • 10 Agata J, Masuda A, Takada M, Hagishiura K, Murakami H, Miyazaki Y, Shimamoto K. High plasma immunoreactive leptin level in essential hypertension.  Am J Hypertens. 1997;  10 1171-1174
    CrossrefPubMedGoogle Scholar
  • 11 Hirose H, Saito I, Tsujioka M, Mori M, Kawabe H, Saruta T. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents.  J Hypertens. 1998;  16 2007-2012
    PubMedGoogle Scholar
  • 12 Suter P M, Locher R, Häsler E, Vetter W. Is there a role of the ob gene product leptin in essential hypertension?.  Am J Hypertens. 1998;  11 1305-1311
    CrossrefPubMedGoogle Scholar
  • 13 Kokot F, Adamczak M, Wiežcek A, Cieplok J. Does leptin play a role in the pathogenesis of essential hypertension?.  Kidney Blood Pres Res. 1999;  22 154-160
    PubMedGoogle Scholar
  • 14 Adamczak M, Kokot F, Wiežcek A. Relationship between plasma renin profile and leptinaemia in patients with essential hypertension.  J Hum Hypertens. 2000;  14 503-509
    CrossrefPubMedGoogle Scholar
  • 15 Saad M F, Riad-Gabriel M G, Khan A, Sharma A, Michael R, Jinagouda S D, Boyadjian R, Steil G M. Diurnal and ultradian rhythmicity of plasma leptin: effect of gender and adiposity.  J Clin Endocrinol Metab. 1998;  83 1706-1712
    CrossrefPubMedGoogle Scholar
  • 16 Jones D W. Body weight and blood pressure. Effects of weight reduction on hypertension.  Am J Hypertens. 1996;  9 50S-54S
    CrossrefPubMedGoogle Scholar
  • 17 Tuck M L, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure. Plasma renin activity and plasma aldosterone levels in obese patients.  N Engl J Med. 1981;  304 930-933
    CrossrefPubMedGoogle Scholar
  • 18 Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension.  J Hypertens. 1999;  17 151-183
    PubMedGoogle Scholar
  • 19 Joint National Committee on Prevation, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Sixth report.  Arch Intern Med. 1997;  157 2413-2446
    CrossrefPubMedGoogle Scholar
  • 20 Kokot F, Wiežcek A, Schmidt-Gayk H, Marcinkowski W, Gilge U, Heidland A, Rudka R, Trembecki J. Function of endocrine organs in hemodialyzed patients on long-term erythropoietin therapy.  Artif Organs. 1995;  19 428-435
    PubMedGoogle Scholar
  • 21 Kalsbeek A, Fliers E, Romijn J A, La Fleur S E, Wortel J, Bakker O, Endert E, Buijs R M. The suprachiasmatic nucleus generates the diurnal changes in plasma leptin levels.  Endocrinology. 2001;  142 2677-2685
    CrossrefPubMedGoogle Scholar
  • 22 Corica F, Corsonello A, Lentile R, de Gregorio T, Malara A, Artemisia A, Buemi M. Leptin and norepinephrine plasma concentrations during glucose loading in normotensive and hypertensive obese women.  Am J Hypertens. 2001;  9 50S-54S
    PubMedGoogle Scholar
  • 23 Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F, Ozata M. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension.  J Renin Angiotensin Aldosterone Syst. 2001;  2 112-116
    PubMedGoogle Scholar
  • 24 Matsuo K, Mikami H, Ogihara T, Tuck M L. Weight reduction and pharmacologic treatment in obese hypertensives.  Am J Hypertens. 2001;  14 530-538
    CrossrefPubMedGoogle Scholar
  • 25 Kim S, Whelan J, Claycombe K, Reath D B, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3Ts-L1 and human adipocytes via a prostaglandin-independent mechanism.  J Nutr. 2002;  132 1135-1140
    PubMedGoogle Scholar
  • 26 Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group.  Cardiovasc Drugs Ther. 2000;  14 67-75
    CrossrefPubMedGoogle Scholar
  • 27 Cammisotto P G, Bukowiecki L J. Mechanisms of leptin secretion from white adipocytes.  Am J Physiol Cell Physiol. 2002;  283 C244-C250
    PubMedGoogle Scholar
  • 28 Pinkey J H, Coppack S W, Mohamed Ali V. Effect of isoprenaline on plasma leptin and lipolysis in humans.  Clin Endocrinol (Oxf). 1998;  48 407-411
    CrossrefPubMedGoogle Scholar
  • 29 Carruli L, Ferrari S, Bertolini M, Tagliafico E, Del Rio G. Regulation of ob gene expression: evidence for epinephrine-induced suppression in human obesity.  J Clin Endocrinol Metab. 1999;  84 3309-3312
    CrossrefPubMedGoogle Scholar
  • 30 Bottner A, Eisenhofer G, Torpy D J, Ehrhart-Bornstein M, Keiser H R, Chrousos G P, Bornstein S R. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients.  Metabolism. 1999;  48 543-545
    CrossrefPubMedGoogle Scholar
  • 31 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.  Hypertension. 2001;  37 250-254
    CrossrefPubMedGoogle Scholar
  • 32 Kunz I, Schorr U, Klaus S, Sharma A M. Resting metabolic rate and substrate use in obesity hypertension.  Hypertension. 2000;  36 26-32
    PubMedGoogle Scholar
  • 33 Astrup A, Simonsen L, Bulow J, Madsen J, Christensen N J. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle.  Am J Physiol. 1989;  257 E340-E345
    PubMedGoogle Scholar
  • 34 Ravussin E, Pratley R E, Maffei M, Wang H, Friedman J M, Bennett P H, Bogardus C. Relatively low plasma leptin concentration precedes weight gain in Pima Indians.  Nature Med. 1997;  3 238-240
    PubMedGoogle Scholar
  • 35 Mavri A, Stegnar M, Sabovic M. Do vaseline serum leptin levels predict weight regain after dieting in obese women?.  Diab Obes Metab. 2001;  3 293-298
    PubMedGoogle Scholar
  • 36 Schmieder R E, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment.  Br Med J. 1992;  307 537-540
    PubMedGoogle Scholar
  • 37 Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.  Horm Metab Res. 2001;  33 167-169
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in double-blind cross-over study in hypertensive patients.  Blood Press. 1992;  1 92-101
    PubMedGoogle Scholar
  • 39 Reneland R, Alvarez E, Andrersson P E, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long treatment with atenolol or trandolapril.  J Hum Hypertens. 2000;  14 175-180
    CrossrefPubMedGoogle Scholar

Prof. Dr. hab. med. A. Wiežcek

Department of Nephrology, Endocrinology and Metabolic Diseases ·

Silesian University School of Medicine · Francuska Str. 20 - 24 · 40-027 Katowice · Poland ·

Phone: + 48 (32) 255 26 95

Fax: + 48 (32) 255 37 26

Email: awiecek@spskm.katowice.pl